RiverVest Venture Fund V, L.P.
Follow-ons only
Follow-ons only: first sale Oct 2020, per Form D (fund age approximates vintage)
- Vintage
- 2020
- Fund size
- $275M (Form D)
- Stages
- Not stated
- Sectors
- Biotech, Medical devices
- Regions
- Not stated
01 · Thesis
RiverVest Venture Fund V, L.P. backs life science companies addressing significant unmet medical needs. Its portfolio company Bluejay Therapeutics has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals.
02 · Initial check
$2.75M to $4.58M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Jay W. Schmelter, Co-Founder & Managing Director
- John McKearn, Manager of the GP LLC.
- Niall O'Donnell, Manager of the GP LLC.
04 · Deals
- Bluejay Therapeutics source
05 · Evidence
Fund V backs life science companies addressing significant unmet medical needs, such as Bluejay Therapeutics.
RiverVest Fund V is raised with $275M in commitments.
https://rivervest.com/about/Bluejay Therapeutics
Bluejay Therapeutics – a RiverVest Venture Fund V portfolio company – has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals, Inc.
https://rivervest.com/2025/12/09/portfolio-company-bluejay-therapeutics-to-be-acquired-by-mirum-pharmaceuticals/
06 · Sources
Last verified: Oct 25, 2026